Drug intelligence / Profile preview

ONX-2006

Development stage: Preclinical
Lead developer: Onselex Pharmaceuticals
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Oral

Overview

ONX-2006 is an orally administered nanoparticle-based anticancer drug candidate developed for the treatment of gastric and colorectal cancers. It is being developed as a pill formulation, leveraging advanced nanotechnology to enhance delivery and efficacy against tumors in these indications. The drug is part of a pipeline that includes other targeted therapies for various solid tumors[1].

Beyond the preview

Go deeper on ONX-2006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ONX-2006.

Explore the full profile